Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 10 studies | 28% ± 9% | |
endothelial cell | 9 studies | 23% ± 12% | |
epithelial cell | 7 studies | 21% ± 4% | |
microglial cell | 7 studies | 28% ± 8% | |
glutamatergic neuron | 6 studies | 50% ± 19% | |
macrophage | 6 studies | 24% ± 6% | |
GABAergic neuron | 6 studies | 36% ± 13% | |
neuron | 5 studies | 30% ± 14% | |
interneuron | 5 studies | 41% ± 14% | |
granule cell | 4 studies | 41% ± 20% | |
oligodendrocyte precursor cell | 4 studies | 21% ± 3% | |
fibroblast | 3 studies | 30% ± 18% | |
transit amplifying cell | 3 studies | 24% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 9 studies | 36% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 1716.16 | 577 / 578 | 100% | 22.21 | 1152 / 1155 |
esophagus | 100% | 1419.77 | 1444 / 1445 | 99% | 20.74 | 182 / 183 |
intestine | 100% | 1646.64 | 966 / 966 | 99% | 31.35 | 523 / 527 |
breast | 100% | 1632.52 | 459 / 459 | 99% | 34.81 | 1107 / 1118 |
stomach | 100% | 1148.68 | 358 / 359 | 99% | 29.34 | 282 / 286 |
uterus | 100% | 1244.28 | 170 / 170 | 97% | 16.29 | 444 / 459 |
liver | 100% | 1775.30 | 226 / 226 | 96% | 14.69 | 390 / 406 |
pancreas | 98% | 729.67 | 322 / 328 | 98% | 15.06 | 174 / 178 |
ovary | 100% | 1651.43 | 180 / 180 | 95% | 12.81 | 410 / 430 |
skin | 100% | 1673.18 | 1804 / 1809 | 96% | 29.36 | 451 / 472 |
thymus | 100% | 870.37 | 651 / 653 | 94% | 10.84 | 571 / 605 |
kidney | 100% | 1478.97 | 89 / 89 | 94% | 15.16 | 845 / 901 |
prostate | 100% | 1063.15 | 245 / 245 | 92% | 8.79 | 462 / 502 |
brain | 98% | 2921.89 | 2597 / 2642 | 93% | 10.07 | 655 / 705 |
bladder | 100% | 1080.43 | 21 / 21 | 90% | 19.26 | 456 / 504 |
adrenal gland | 100% | 2420.06 | 258 / 258 | 88% | 16.27 | 203 / 230 |
spleen | 100% | 780.77 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 1535.25 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 894.94 | 854 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 848.47 | 1315 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 20.63 | 44 / 45 |
muscle | 91% | 493.57 | 727 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 84% | 14.39 | 67 / 80 |
lymph node | 0% | 0 | 0 / 0 | 41% | 2.25 | 12 / 29 |
peripheral blood | 32% | 131.85 | 293 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0031345 | Biological process | negative regulation of cell projection organization |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0015012 | Biological process | heparan sulfate proteoglycan biosynthetic process |
GO_0060391 | Biological process | positive regulation of SMAD protein signal transduction |
GO_0030210 | Biological process | heparin biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0016857 | Molecular function | racemase and epimerase activity, acting on carbohydrates and derivatives |
GO_0005509 | Molecular function | calcium ion binding |
GO_0047464 | Molecular function | heparosan-N-sulfate-glucuronate 5-epimerase activity |
Gene name | GLCE |
Protein name | heparosan-N-sulfate-glucuronate 5-epimerase (EC 5.1.3.17) D-glucuronyl C5-epimerase (EC 5.1.3.17) (Heparan sulfate C5-epimerase) (Hsepi) (Heparin/heparan sulfate:glucuronic acid C5-epimerase) (Heparosan-N-sulfate-glucuronate 5-epimerase) |
Synonyms | KIAA0836 |
Description | FUNCTION: Converts D-glucuronic acid residues adjacent to N-sulfate sugar residues to L-iduronic acid residues, both in maturing heparan sulfate (HS) and heparin chains. This is important for further modifications that determine the specificity of interactions between these glycosaminoglycans and proteins. . |
Accessions | H0YNP1 ENST00000261858.7 ENST00000559420.2 O94923 |